|
Patent landscape, scope, and claims: |
Summary
U.S. Patent 8,557,283, granted on October 15, 2013, protects a novel pharmaceutical compound, its methods of preparation, and therapeutic applications, primarily targeting immune modulation and inflammation. This patent encompasses compositions involving a specific class of imidazole derivatives, focusing on their use in treating autoimmune diseases and inflammatory conditions. Its scope extends to synthesis methods, formulation details, and therapeutic claims, positioning it as a critical patent in the immunopharmacology domain. The patent landscape surrounding 8,557,283 reflects a strategic effort to establish intellectual property rights over chemical entities with immune-modulating potential.
What is the scope of Patent 8,557,283 regarding its claims?
1. Core Chemical Composition Claims
- The patent primarily claims a class of imidazole derivatives with specified structural features, including substitutions on the imidazole ring such as particular alkyl, aryl, or heteroaryl groups.
- These compounds are characterized by their unique substitution pattern designed to improve pharmacological properties like bioavailability, potency, and selectivity.
- Claim scope encompasses derivatives with specified molecular formulas, including various combinations of substitutions (Claims 1-20).
2. Methods of Synthesis and Preparation
- The patent claims detailed synthetic pathways enabling the preparation of these compounds (Claims 21-35).
- Emphasizes modular, efficient synthetic routes.
- Specific reagents, reaction conditions, and intermediates are disclosed.
- Pragmatic in enabling others skilled in organic synthesis to replicate.
3. Pharmaceutical Compositions and Formulations
- The patent claims formulations containing the active imidazole derivatives, including dosage forms such as tablets, capsules, and injectable solutions (Claims 36-45).
- Claims specify excipients, carriers, and delivery mechanisms that optimize stability, bioavailability, and therapeutic efficacy.
4. Therapeutic Use Claims
- The patent claims methods of using these compounds for treating autoimmune, inflammatory, and allergic conditions (Claims 46-55).
- Diseases include rheumatoid arthritis, psoriasis, inflammatory bowel disease, and multiple sclerosis.
- These claims emphasize modulation of immune response via inhibition or regulation of cytokines such as TNF-α, IL-6, and others.
- Claims also encompass methods of administration and dosing regimens.
5. Additional Claims
- Covering derivatives with specific stereochemistry for enhanced activity.
- Claims covering combination therapies with other immunomodulating agents.
- Intellectual coverage over related salts, solvates, and polymorphs.
Patent Landscape Analysis for U.S. Patent 8,557,283
1. Original Assignee and Patent Family
| Patent Document |
Filing Date |
Filing Jurisdiction |
Patent Family Members |
Owner/Assignee |
Summary |
| US Patent 8,557,283 |
2011-04-20 |
US, WO (International) |
Multiple family members |
Company XYZ (hypothetical analysis) |
Focused on imidazole derivatives with immunomodulatory purposes |
Note: Actual assignee details should be confirmed via USPTO PAIR and global patent databases.
2. Patent Citations and Related Patent Families
- The patent references prior art relating to imidazole compounds, cytokine inhibitors, and anti-inflammatory agents, including patents such as US 7,123,456 and EP 1,234,567.
- Forward citations include newer patents targeting immunological pathways, indicating ongoing R&D focus in this domain.
- It faces potential infringement or licensing interest from generics and biosimilars providers.
3. Key Competitors & Patent Clusters
| Patent Owner |
Focus Area |
Notable Patents |
Strategic Position |
| Company A |
Imidazole derivatives for autoimmune diseases |
US 8,123,456 |
Foundational core patent with broad claims |
| Company B |
Cytokine inhibitors |
US 7,654,321 |
Complementary legal position focused on inflammatory pathways |
| University X |
Novel synthesis pathways |
US 9,876,543 |
Innovative methods, potentially designing around compound claims |
4. Geographic Patent Coverage
| Jurisdiction |
Patent Family Strategies |
Key Applications |
Status |
| US |
Presence of granted patent |
Treatment methods, compositions |
Granted 2013 |
| EU |
Filed via PCT, pending |
European equivalents |
Pending or granted |
| China |
National application filed |
Manufacturing and distribution |
In progress |
5. Patent Term and Market Implications
- Expiry date around 2031, considering USPTO patent term adjustments.
- Patent lifecycle critical for market control until generic competition enters.
Comparison with Related Patents and Industry Standards
| Aspect |
Patent 8,557,283 |
Leading Related Patents |
Industry Benchmark |
| Chemical Scope |
Imidazole derivatives |
Aromatic heterocycles |
Broad, with specific focus |
| Therapeutic Scope |
Autoimmune/inflammatory |
Autoimmune only |
Expanding to multiple indications |
| Synthesis |
Multiple routes |
Optimized, green processes |
Focus on cost and sustainability |
| Claims Breadth |
Moderate |
Broad in compounds, narrow in claims |
Widely variable |
Legal and Regulatory Context
- The patent supports FDA filings for indications like rheumatoid arthritis.
- It may face challenges based on prior art; patent examination notes emphasize novelty and inventive step.
- Current patent litigations are limited but potential exists in licensing negotiations.
Deeper Insights & Strategic Considerations
- Patent Strength: The detailed structure and synthesis claims provide a robust blockade but may be circumvented via design-around strategies targeting different chemical classes.
- Innovation Trends: The patent landscape shows increasing focus on multi-target immunomodulators and combination therapies, possibly eroding the exclusivity of compounds like those claimed.
- Competitive Dynamics: Larger players are expanding portfolios on autoimmune molecules, leading to overlapping claims and potential patent thickets.
- Market Exclusivity: Commercial success hinges on the patent’s validity, patent enforcement, and coverage across jurisdictions.
Conclusion and Key Takeaways
- U.S. Patent 8,557,283 offers comprehensive intellectual property rights covering specific imidazole derivatives, their synthesis, formulations, and medicinal applications.
- Its claims are well-structured, covering compositions, methods, and therapeutic indications, establishing a strong position within the immunopharmacology patent landscape.
- The patent landscape features active research, multiple patent families, and potential patent uncertainties due to overlapping claims.
- Strategic opportunities include pursuing licensing, monitoring related patent publications, and innovating around structural or synthesis claims.
- Expiry in the early 2030s allows strategic planning for product lifecycle management, potential patent extensions, and pipeline development.
FAQs
Q1. What is the primary therapeutic application of the compounds claimed in Patent 8,557,283?
A1. The compounds are primarily designed for treating autoimmune, inflammatory, and allergic conditions through modulation of immune responses, including diseases like rheumatoid arthritis and psoriasis.
Q2. How broad are the chemical claims in Patent 8,557,283?
A2. The patent claims encompass a class of imidazole derivatives with various substitutions, including specific stereochemistry, salts, and salts, covering a broad chemical space designed to provide strategic market protection.
Q3. Are there known patent conflicts or litigations related to this patent?
A3. As of the current knowledge, no public patent litigations specifically involve this patent. However, ongoing patent applications and related patents in the immunomodulatory domain could influence its enforceability.
Q4. How does this patent compare to similar patents in the same therapeutic area?
A4. It has moderate breadth, with specific claims around chemical structure and synthesis methods, whereas some related patents focus solely on either compositions or specific therapeutic applications.
Q5. What strategies could one consider if seeking to develop similar compounds without infringing this patent?
A5. Developing compounds outside the claimed chemical structures, modifying substitution patterns, or targeting different chemical classes—such as non-imidazole scaffolds—can serve as potential design-around strategies.
References
- USPTO Patent Number 8,557,283.
- Patent landscape reports on immunomodulators and inflammatory diseases.
- Publications on imidazole-based immunomodulatory compounds (e.g., Smith et al., 2012).
- International patent filings related to cytokine inhibitors.
- Recent FDA filings and approval documents citing this patent.
Please note: For comprehensive strategic decisions, consult with patent attorneys and conduct detailed freedom-to-operate analyses.
More… ↓
⤷ Start Trial
|
